Non-Hodgkin Lymphoma - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 1740 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

Non-Hodgkin lymphoma (also known as non-Hodgkin lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 28, 137, 124, 5, 123, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 15, 17, 16 and 4 molecules, respectively.

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 11
Non-Hodgkin Lymphoma - Overview 12
Non-Hodgkin Lymphoma - Therapeutics Development 13
Non-Hodgkin Lymphoma - Therapeutics Assessment 85
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 111
Non-Hodgkin Lymphoma - Drug Profiles 233
Non-Hodgkin Lymphoma - Dormant Projects 1656
Non-Hodgkin Lymphoma - Discontinued Products 1676
Non-Hodgkin Lymphoma - Product Development Milestones 1684
Appendix 1692

List of Tables

Number of Products under Development for Non-Hodgkin Lymphoma, H1 2017 60
Number of Products under Development by Companies, H1 2017 62
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 63
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 64
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 65
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 66
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 67
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 68
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 69
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 70
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 71
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 72
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 73
Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017 74
Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017 75
Number of Products under Development by Universities/Institutes, H1 2017 76
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 77
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 78
Products under Development by Companies, H1 2017 79
Products under Development by Companies, H1 2017 (Contd..1), H1 2017 80
Products under Development by Companies, H1 2017 (Contd..2), H1 2017 81
Products under Development by Companies, H1 2017 (Contd..3), H1 2017 82
Products under Development by Companies, H1 2017 (Contd..4), H1 2017 83
Products under Development by Companies, H1 2017 (Contd..5), H1 2017 84
Products under Development by Companies, H1 2017 (Contd..6), H1 2017 85
Products under Development by Companies, H1 2017 (Contd..7), H1 2017 86
Products under Development by Companies, H1 2017 (Contd..8), H1 2017 87
Products under Development by Companies, H1 2017 (Contd..9), H1 2017 88
Products under Development by Companies, H1 2017 (Contd..10), H1 2017 89
Products under Development by Companies, H1 2017 (Contd..11), H1 2017 90
Products under Development by Companies, H1 2017 (Contd..12), H1 2017 91
Products under Development by Companies, H1 2017 (Contd..13), H1 2017 92
Products under Development by Companies, H1 2017 (Contd..14), H1 2017 93
Products under Development by Companies, H1 2017 (Contd..15), H1 2017 94
Products under Development by Companies, H1 2017 (Contd..16), H1 2017 95
Products under Development by Companies, H1 2017 (Contd..17), H1 2017 96
Products under Development by Companies, H1 2017 (Contd..18), H1 2017 97
Products under Development by Companies, H1 2017 (Contd..19), H1 2017 98
Products under Development by Companies, H1 2017 (Contd..20), H1 2017 99
Products under Development by Companies, H1 2017 (Contd..21), H1 2017 100
Products under Development by Companies, H1 2017 (Contd..22), H1 2017 101
Products under Development by Companies, H1 2017 (Contd..23), H1 2017 102
Products under Development by Companies, H1 2017 (Contd..24), H1 2017 103
Products under Development by Companies, H1 2017 (Contd..25), H1 2017 104
Products under Development by Companies, H1 2017 (Contd..26), H1 2017 105
Products under Development by Companies, H1 2017 (Contd..27), H1 2017 106
Products under Development by Companies, H1 2017 (Contd..28), H1 2017 107
Products under Development by Companies, H1 2017 (Contd..29), H1 2017 108
Products under Development by Companies, H1 2017 (Contd..30), H1 2017 109
Products under Development by Companies, H1 2017 (Contd..31), H1 2017 110
Products under Development by Companies, H1 2017 (Contd..32), H1 2017 111
Products under Development by Companies, H1 2017 (Contd..33), H1 2017 112
Products under Development by Companies, H1 2017 (Contd..34), H1 2017 113
Products under Development by Companies, H1 2017 (Contd..35), H1 2017 114
Products under Development by Companies, H1 2017 (Contd..36), H1 2017 115
Products under Development by Companies, H1 2017 (Contd..37), H1 2017 116
Products under Development by Companies, H1 2017 (Contd..38), H1 2017 117
Products under Development by Companies, H1 2017 (Contd..39), H1 2017 118
Products under Development by Companies, H1 2017 (Contd..40), H1 2017 119
Products under Development by Companies, H1 2017 (Contd..41), H1 2017 120
Products under Development by Companies, H1 2017 (Contd..42), H1 2017 121
Products under Development by Companies, H1 2017 (Contd..43), H1 2017 122
Products under Development by Companies, H1 2017 (Contd..44), H1 2017 123
Products under Development by Companies, H1 2017 (Contd..45), H1 2017 124
Products under Development by Companies, H1 2017 (Contd..46), H1 2017 125
Products under Development by Companies, H1 2017 (Contd..47), H1 2017 126
Products under Development by Universities/Institutes, H1 2017 127
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 128
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 129
Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 131
Number of Products by Stage and Target, H1 2017 133
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 134
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 135
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 136
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 137
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 138
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 139
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 140
Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017 141
Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017 142
Number of Products by Stage and Mechanism of Action, H1 2017 144
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 145
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 146
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 147
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 148
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 149
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 150
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 151
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017 152
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017 153
Number of Products by Stage and Route of Administration, H1 2017 155
Number of Products by Stage and Molecule Type, H1 2017 157
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2017 158
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2017 158
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2017 159
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2017 160
Non-Hodgkin Lymphoma - Pipeline by ACEA Biosciences Inc, H1 2017 162
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H1 2017 162
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2017 163
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H1 2017 164
Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H1 2017 164
Non-Hodgkin Lymphoma - Pipeline by Aileron Therapeutics Inc, H1 2017 165
Non-Hodgkin Lymphoma - Pipeline by Alfa Wassermann SpA, H1 2017 165
Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2017 166
Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H1 2017 166
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H1 2017 167
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2017 168
Non-Hodgkin Lymphoma - Pipeline by Aptose Biosciences Inc, H1 2017 168
Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2017 169
Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics Inc, H1 2017 169
Non-Hodgkin Lymphoma - Pipeline by ArQule Inc, H1 2017 170
Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H1 2017 170
Non-Hodgkin Lymphoma - Pipeline by Arven Ilac, H1 2017 171
Non-Hodgkin Lymphoma - Pipeline by Arvinas Inc, H1 2017 171
Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H1 2017 172
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H1 2017 172
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H1 2017 173
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2017 173
Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics Inc, H1 2017 174
Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017 174
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2017 175
Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H1 2017 177
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 177
Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H1 2017 178
Non-Hodgkin Lymphoma - Pipeline by BioAtla LLC, H1 2017 178
Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H1 2017 179
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2017 179
Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H1 2017 180
Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H1 2017 180
Non-Hodgkin Lymphoma - Pipeline by BioNTech AG, H1 2017 181
Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H1 2017 181
Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H1 2017 182
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017 182
Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H1 2017 183
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 183
Non-Hodgkin Lymphoma - Pipeline by Calimmune Inc, H1 2017 184
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H1 2017 184
Non-Hodgkin Lymphoma - Pipeline by Cascadian Therapeutics Inc, H1 2017 185
Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H1 2017 186
Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H1 2017 188
Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H1 2017 188
Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H1 2017 189
Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H1 2017 189
Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H1 2017 190
Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H1 2017 191
Non-Hodgkin Lymphoma - Pipeline by Celleron Therapeutics Ltd, H1 2017 191
Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H1 2017 192
Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H1 2017 193
Non-Hodgkin Lymphoma - Pipeline by Celon Pharma SA, H1 2017 194
Non-Hodgkin Lymphoma - Pipeline by Centrose LLC, H1 2017 194
Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H1 2017 195
Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2017 195
Non-Hodgkin Lymphoma - Pipeline by Cleave Biosciences Inc, H1 2017 196
Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SAS, H1 2017 196
Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences Inc, H1 2017 197
Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals Inc, H1 2017 197
Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017 198
Non-Hodgkin Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H1 2017 198
Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp, H1 2017 199
Non-Hodgkin Lymphoma - Pipeline by Curis Inc, H1 2017 200
Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017 201
Non-Hodgkin Lymphoma - Pipeline by CytomX Therapeutics Inc, H1 2017 201
Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 202
Non-Hodgkin Lymphoma - Pipeline by Debiopharm International SA, H1 2017 202
Non-Hodgkin Lymphoma - Pipeline by Denovo Biopharma LLC, H1 2017 203
Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corp, H1 2017 203
Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics Inc, H1 2017 204
Non-Hodgkin Lymphoma - Pipeline by Eisai Co Ltd, H1 2017 204
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2017 205
Non-Hodgkin Lymphoma - Pipeline by EpiZyme Inc, H1 2017 206
Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H1 2017 207
Non-Hodgkin Lymphoma - Pipeline by Evotec AG, H1 2017 207
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 208
Non-Hodgkin Lymphoma - Pipeline by Forma Therapeutics Inc, H1 2017 209
Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals Inc, H1 2017 209
Non-Hodgkin Lymphoma - Pipeline by Forty Seven Inc, H1 2017 210
Non-Hodgkin Lymphoma - Pipeline by Galderma SA, H1 2017 210
Non-Hodgkin Lymphoma - Pipeline by Genentech Inc, H1 2017 211
Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co Ltd, H1 2017 212
Non-Hodgkin Lymphoma - Pipeline by Genosco Inc, H1 2017 212
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences Inc, H1 2017 213
Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2017 214
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional SA, H1 2017 214
Non-Hodgkin Lymphoma - Pipeline by H3 Biomedicine Inc, H1 2017 215
Non-Hodgkin Lymphoma - Pipeline by Heidelberg Pharma GmbH, H1 2017 215
Non-Hodgkin Lymphoma - Pipeline by Humorigin Biotechnology Corp, H1 2017 216
Non-Hodgkin Lymphoma - Pipeline by Hutchison China MediTech Ltd, H1 2017 216
Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H1 2017 217
Non-Hodgkin Lymphoma - Pipeline by IGF Oncology LLC, H1 2017 217
Non-Hodgkin Lymphoma - Pipeline by Ignyta Inc, H1 2017 218
Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp, H1 2017 218
Non-Hodgkin Lymphoma - Pipeline by ImmunGene Inc, H1 2017 219
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen Inc, H1 2017 219
Non-Hodgkin Lymphoma - Pipeline by Immunomedics Inc, H1 2017 220
Non-Hodgkin Lymphoma - Pipeline by Immunovaccine Inc, H1 2017 221
Non-Hodgkin Lymphoma - Pipeline by Immunwork Inc, H1 2017 221
Non-Hodgkin Lymphoma - Pipeline by Incyte Corp, H1 2017 222
Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Ltd, H1 2017 223
Non-Hodgkin Lymphoma - Pipeline by Innate Pharma SA, H1 2017 223
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics Inc, H1 2017 224
Non-Hodgkin Lymphoma - Pipeline by Japan Tobacco Inc, H1 2017 224
Non-Hodgkin Lymphoma - Pipeline by JHL Biotech Inc, H1 2017 225
Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2017 225
Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc, H1 2017 226
Non-Hodgkin Lymphoma - Pipeline by K-Stemcell Co Ltd, H1 2017 227
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine Inc, H1 2017 227
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017 228
Non-Hodgkin Lymphoma - Pipeline by Kite Pharma Inc, H1 2017 229
Non-Hodgkin Lymphoma - Pipeline by Klyss Biotech Inc, H1 2017 230
Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co Ltd, H1 2017 230
Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017 231
Non-Hodgkin Lymphoma - Pipeline by LFB SA, H1 2017 231
Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H1 2017 232
Non-Hodgkin Lymphoma - Pipeline by MacroGenics Inc, H1 2017 233
Non-Hodgkin Lymphoma - Pipeline by MedImmune LLC, H1 2017 233
Non-Hodgkin Lymphoma - Pipeline by Medivir AB, H1 2017 234
Non-Hodgkin Lymphoma - Pipeline by MEI Pharma Inc, H1 2017 234
Non-Hodgkin Lymphoma - Pipeline by MENTRIK Biotech LLC, H1 2017 235
Non-Hodgkin Lymphoma - Pipeline by Merck & Co Inc, H1 2017 236
Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2017 237
Non-Hodgkin Lymphoma - Pipeline by Mesoblast Ltd, H1 2017 238
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 239
Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics Inc, H1 2017 240
Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc, H1 2017 240
Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc, H1 2017 241
Non-Hodgkin Lymphoma - Pipeline by Moleculin Biotech Inc, H1 2017 241
Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd, H1 2017 242
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2017 242
Non-Hodgkin Lymphoma - Pipeline by NantKwest Inc, H1 2017 243
Non-Hodgkin Lymphoma - Pipeline by NBE-Therapeutics AG, H1 2017 243
Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc, H1 2017 244
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2017 244
Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017 245
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2017 246
Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H1 2017 246
Non-Hodgkin Lymphoma - Pipeline by Oncobiologics Inc, H1 2017 247
Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics Inc, H1 2017 247
Non-Hodgkin Lymphoma - Pipeline by Oncopeptides AB, H1 2017 248
Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Inc, H1 2017 248
Non-Hodgkin Lymphoma - Pipeline by Oncovir Inc, H1 2017 249
Non-Hodgkin Lymphoma - Pipeline by Oncternal Therapeutics Inc, H1 2017 249
Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 250
Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H1 2017 251
Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H1 2017 251
Non-Hodgkin Lymphoma - Pipeline by OXIS International Inc, H1 2017 253
Non-Hodgkin Lymphoma - Pipeline by Patrys Ltd, H1 2017 253
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc, H1 2017 254
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar SA, H1 2017 254
Non-Hodgkin Lymphoma - Pipeline by Philogen SpA, H1 2017 255
Non-Hodgkin Lymphoma - Pipeline by PIQUR Therapeutics AG, H1 2017 255
Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017 255
Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals Inc, H1 2017 256
Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd, H1 2017 256
Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 257
Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H1 2017 257
Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H1 2017 258
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt, H1 2017 258
Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H1 2017 259
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2017 259
Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H1 2017 260
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics Inc, H1 2017 261
Non-Hodgkin Lymphoma - Pipeline by Selvita SA, H1 2017 262
Non-Hodgkin Lymphoma - Pipeline by Senhwa Biosciences Inc, H1 2017 262
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017 263
Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017 263
Non-Hodgkin Lymphoma - Pipeline by Sierra Oncology Inc, H1 2017 264
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau SpA, H1 2017 264
Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H1 2017 265
Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma KK, H1 2017 265
Non-Hodgkin Lymphoma - Pipeline by Soligenix Inc, H1 2017 266
Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics Inc, H1 2017 266
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017 267
Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics Inc, H1 2017 268
Non-Hodgkin Lymphoma - Pipeline by Sunesis Pharmaceuticals Inc, H1 2017 269
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc, H1 2017 269
Non-Hodgkin Lymphoma - Pipeline by Surface Oncology Inc, H1 2017 270
Non-Hodgkin Lymphoma - Pipeline by Sutro Biopharma Inc, H1 2017 270
Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017 270
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company Ltd, H1 2017 271
Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc, H1 2017 271
Non-Hodgkin Lymphoma - Pipeline by Targazyme Inc, H1 2017 272
Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 272
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics Inc, H1 2017 273
Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2017 273
Non-Hodgkin Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H1 2017 274
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Ltd, H1 2017 274
Non-Hodgkin Lymphoma - Pipeline by Transgene SA, H1 2017 275
Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc, H1 2017 275
Non-Hodgkin Lymphoma - Pipeline by United BioPharma Inc, H1 2017 276
Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics Inc, H1 2017 276
Non-Hodgkin Lymphoma - Pipeline by Verastem Inc, H1 2017 277
Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H1 2017 277
Non-Hodgkin Lymphoma - Pipeline by Xencor Inc, H1 2017 278
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences Inc, H1 2017 278
Non-Hodgkin Lymphoma - Pipeline by ZIOPHARM Oncology Inc, H1 2017 279
Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc, H1 2017 279
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 1703
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..1), H1 2017 1704
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..2), H1 2017 1705
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..3), H1 2017 1706
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..4), H1 2017 1707
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..5), H1 2017 1708
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..6), H1 2017 1710
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..7), H1 2017 1711
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..8), H1 2017 1712
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..9), H1 2017 1713
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..10), H1 2017 1714
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..11), H1 2017 1715
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..12), H1 2017 1716
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..13), H1 2017 1717
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..14), H1 2017 1718
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..15), H1 2017 1719
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..16), H1 2017 1720
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..17), H1 2017 1721
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..18), H1 2017 1722
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 1723
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..1), H1 2017 1724
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..2), H1 2017 1725
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..3), H1 2017 1726
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..4), H1 2017 1727
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..5), H1 2017 1728
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..6), H1 2017 1729
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..7), H1 2017 1730